Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab.

Intriguingly, although high PD-L1 seemed to be associated with RR independently of NLR, a nonsignificant trend toward better OS in patients with low NLR and high PD-L1 as compared to those with high NLR and high PD-L1 was observed.

also in 5,406 other papers